Sorry, you need to enable JavaScript to visit this website.

DVT: Managing Recurrent Risk | XARELTO® (rivaroxaban)

Managing ongoing risk for recurrent DVT

If you’ve completed at least 6 months of DVT treatment, it’s important to understand that certain risk factors—primarily ones that you can’t change or control—may mean you have an ongoing risk for recurrent DVT blood clots. See why it’s important to help protect yourself from another DVT, and how XARELTO® can help.

What DVT risk factors contribute to recurrent DVT?

  • A previous DVT or pulmonary embolism (PE)
  • Having certain blood disorders that make your blood more likely to clot (eg, factor V Leiden, a mutation of one of the clotting factors involved in normal blood clotting)
  • Older age (being older than 60 is a risk factor for DVT)

If you stop taking a blood thinner:

After 5 years,
chance of another

After 10 years,
chance of another

Up to
of future DVT or PE blood clots result in a fatal PE

How do I know if I’m at risk for recurrent DVT?

Your healthcare professional will evaluate your risk factors and may recommend that you continue taking a blood thinner like XARELTO®. This is important because people who have had a DVT or PE and stop taking blood thinners have an even higher chance of having another blood clot.

How and where on the body does a DVT form?

Click or tap on a number, or one of the arrows, to learn more about how a DVT is formed, where on the body one can occur, and the damage that can be done when it is left untreated.

left arrow desktopInfographic showing how the cardiovascular system worksRight arrow desktop

How can XARELTO® help?

Some people may be prescribed aspirin to help prevent them from having another DVT. However, in a clinical trial with at-risk people who had already completed at least 6 months of initial treatment for a DVT, XARELTO® was shown to be superior to aspirin at reducing their risk for recurrent DVT.

  • The risk of another DVT happening again was significantly lower with XARELTO® 10 mg than with aspirin*
  • Less than 1% of patients taking XARELTO® experienced major bleeding, which is similar to the rate of major bleeding in patients taking aspirin to reduce their risk of recurrent DVT or PE*

*After completion of initial treatment lasting at least 6 months.

Image of Diane - DVT

Real people. Real stories.

Hear what it meant to Diane that her husband was being treated with XARELTO®.